Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Avid Bioservices (CDMO) Has Risen 37% in Last One Year, Outperforms Market

If you are looking for the best ideas for your portfolio you may want to consider some of Laughing Water Capital’s top stock picks. Laughing Water Capital, an investment management firm, is bullish on Avid Bioservices Inc. (NASDAQ:CDMO) stock. In its Q2 2019 investor letter – you can download a copy here – the firm discussed its investment thesis on Avid Bioservices Inc. (NASDAQ:CDMO) stock. Avid Bioservices Inc. (NASDAQ:CDMO) is a biotechnology company.

In July 2019, Laughing Water Capital had released its Q2 2019 investor letter. The investment firm said that Avid Bioservices Inc. (NASDAQ:CDMO) was one of the top five positions in Q2 2019. Avid Bioservices Inc. (NASDAQ:CDMO) stock has posted a return of 37.0% in the trailing one year period, outperforming fund’s benchmark the S&P 500 Index which returned 13.3% in the same period. This suggests that the investment firm was right in its decision. On a year-to-date basis, Avid Bioservices Inc. (NASDAQ:CDMO) stock has fallen by 3.5%.

Laughing Water Capital fund posted a return of 10.3% in the second quarter of 2019, outperforming fund’s benchmark the S&P 500 Index which returned 4.30% in the same period. Let’s take a look at comments made by Laughing Water Capital about Avid Bioservices Inc. (NASDAQ:CDMO) stock in the Q2 2019 investor letter.

“Avid Bioservices (CDMO) – Avid was first introduced to the partnership in the 1H’18 letter as a small position, and then appreciated into a mid-sized position. The company is a Contract Drug Manufacturing Organization focused on biologics. In early May the company’s CEO resigned unexpectedly, causing shares to fall more than 20%.

Drilling down past the GAAP numbers reveals that CDMO is essentially a “good co/bad co” situation where the results of a second facility that was built on spec has been a major drag on consolidated results. By way of illustration, looking back at FY16 results and isolating the performance of their first facility reveals that this business formerly ran at ~50% gross margins. However, over the last few quarters as the company has been building out their second facility, consolidated gross margins went negative, and the company had been burning cash.

Following the sell off, shares traded hands at a level where I believed we were paying a fair price for the first facility, and getting the second facility for free. Importantly, management had indicated increasing sales momentum with existing customers as well as new customers, and a board member was perfectly suited to step in as interim CEO. I thus added to our position substantially on the weakness.

Fourth quarter earnings (fiscal year end 4/30) showed CDMO gross margins returning to 20% and positive cash flow as occupancy has risen to a level where operating leverage on the gross margin line has kicked in. This led to the company issuing positive forward guidance, and shares rerated significantly. This is a recession proof business that importantly lies outside the crosshairs of politicians who are eager to attack health care companies and drug companies more specifically. The actual manufacturing cost of pharmaceuticals is a very small piece of the total cost of a drug and regulatory compliance is of vital importance, so even if drug prices come under pressure, the manufacturers are unlikely to be asked to carry any freight. While there are sure to be bumps in the road going forward as customer volume requirements ebb and flow, demand for small batch biologic manufacturing is strong and growing, and it appears as if CDMO has successfully navigated the buildout of their second facility, meaning that this investment is now “good co/good co.”

From this time forward operating leverage should be significant as new sales are realized. Importantly, the company has levers to pull with their capital structure that can increase per share value, and the runway for future growth remains long as CDMO has the potential to once again double existing capacity in the coming years. Notably, this future capacity is likely to ultimately be brought online in conjunction with customer financing, which will be much less painful than the recent speculative capacity expansion. It should be noted that this sort of arrangement is typical for the industry, which is important in context of the risk of industry supply outstripping demand. Quite simply, at the moment demand is exceeding existing supply, and absent speculative building the worst-case scenario should be equilibrium.

Any sort of long-range projections are guaranteed to be wrong and should not be taken too seriously, but it is not unreasonable to think that within 4-5 years CDMO could be well on their way to tripling existing revenue guidance. This would be near the end of their existing growth runway and would thus unlikely deserve a multiple inline with recent industry transactions, but even absent additional growth, recession proof recurring revenue and its associated cash flows deserve high multiples, meaning that in my view CDMO still has multi-bagger potential in the years to come.”

30 Funniest Science Jokes, Puns, and Humor Quotes Ever

Looker_Studio/Shutterstock.com

Last month, we published an article revealing Laughing Water Capital’s bullish investment thesis on Avid Bioservices Inc. (NASDAQ:CDMO) stock in its Q2 2020 investor letter. This suggests that the investment firm has been bullish for a long time on Avid Bioservices Inc. (NASDAQ:CDMO).

In Q1 2020, the number of bullish hedge fund positions on Avid Bioservices Inc. (NASDAQ:CDMO) stock decreased by about 35% from the previous quarter (see the chart here), so a number of other hedge fund managers don’t seem to agree with CDMO’s growth potential. Our calculations showed that Avid Bioservices Inc. (NASDAQ:CDMO) isn’t ranked among the 30 most popular stocks among hedge funds.

The top 10 stocks among hedge funds returned 185% since the end of 2014 and outperformed the S&P 500 Index ETFs by more than 109 percentage points. We know it sounds unbelievable. You have been dismissing our articles about top hedge fund stocks mostly because you were fed biased information by other media outlets about hedge funds’ poor performance. You could have doubled the size of your nest egg by investing in the top hedge fund stocks instead of dumb S&P 500 ETFs. Below you can watch our video about the top 5 hedge fund stocks right now. All of these stocks had positive returns in 2020.

Video: Top 5 Stocks Among Hedge Funds

At Insider Monkey we scour multiple sources to uncover the next great investment idea. For example, legal marijuana is one of the fastest growing industries right now, so we are checking out stock pitches like “the Starbucks of cannabis” to identify the next tenbagger. Federal Reserve has been creating trillions of dollars electronically to keep the interest rates near zero. We believe this will lead to inflation and boost precious metals prices. So, we are checking out this junior gold mining stock. We read hedge fund investor letters and listen to stock pitches at hedge fund conferences. We go through lists like the 10 most profitable companies in the world to pick the best large-cap stocks to buy. Even though we recommend positions in only a tiny fraction of the companies we analyze, we check out as many stocks as we can. You can subscribe to our free enewsletter below to receive our stories in your inbox:

Disclosure: None. This article is originally published at Insider Monkey.